KT502 / Kali Therapeutics - LARVOL DELTA

A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Kali Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Kali Therapeutics, Inc.

First-in-human • New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology